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Abstract
The use of three dimensional in vitro systems in cancer research is a promising path for developing effective
anticancer therapies. The aim of this study was to engineer a functional 3-D in vitro model of normal and cancerous
cervical tissue. Normal epithelial and immortalized cervical epithelial carcinoma cell lines were used to construct 3-D
artiﬁcial normal cervical and cervical cancerous tissues. De-epidermised dermis (DED) was used as a scaffold for
both models. Morphological analyses were conducted by using hematoxylin and eosin staining and characteristics of
the models were studied by analyzing the expression of different structural cytokeratins and differential protein
marker MAX dimerisation protein 1 (Mad1) using immunohistochemical technique. Haematoxylin and eosin staining
results showed that normal cervical tissue had multi epithelial layers while cancerous cervical tissue showed
dysplastic changes. Immunohistochemistry staining revealed that for normal cervix model cytokeratin 10 was
expressed in the upper stratiﬁed layer of the epithelium while cytokeratin 5 was expressed mainly in the middle and
basal layer. Cytokeratin 19 was weakly expressed in a few basal cells. Cervical cancer model showed cytokeratin 19
expression in different epithelial layers and weak or no expression for cytokeratin 5 and cytokeratin 10. Mad1
expression was detected in some suprabasal cells. The 3-D in vitro models showed stratiﬁed epithelial layers and
expressed the same types and patterns of differentiation marker proteins as seen in corresponding in vivo tissue in
either normal cervical or cervical cancerous tissue. These ﬁndings imply that they can serve as functional normal and
cervical cancer models.
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Introduction
In vitro studies are commonly used to mimic the
physiologic environment of tumors[1-2] at early stages of
drug development. When cells are grown as monolayers
in conventional two-dimensional (2-D) models, they
lack the natural three-dimensional (3-D) tissue in vivo
characteristics[3]. 2-D cell cultures can only provide
some approximate information of normal and cancer
tissues due to the highly unnatural geometric and
mechanical limitations imposed on cells[4]. This means
that cells grown in conventional 2-D culture conditions
commonly fail to mimic tissue structure and functions,
and consequently do not provide information about the
✉
Corresponding author: Dr. Xuesong Wen, Department of Natural
Sciences, Middlesex University, The Burroughs, NW4 4BT, UK,
Email: x.wen@mdx.ac.uk; Dr. Lucy Ghali, Department of Natural
Sciences, Middlesex University, The Burroughs, NW4 4BT, UK,
Email: l.ghali@mdx.ac.uk.
Received 15 November 2016, Accepted 20 January 2017, Epub 20
March 2017
CLC number: R71, Document code: A
The authors reported no conﬂict of interests.
This is an open access article under the Creative Commons
Attribution (CC BY 4.0) license, which permits others to distribute,
remix, adapt and build upon this work, for commercial use, provided
the original work is properly cited.
Available online at www.jbr-pub.org
Open Access at PubMed Central
The Journal of Biomedical Research, 2017 31(3): 240–247
© 2017 by the Journal of Biomedical Research. All rights reserved. doi:10.7555/JBR.31.20160150
way cancer cells interact with the extracellular matrix
(ECM) and its complex environment interactions that
exist in human cancers[5]. Under conventional culture
conditions, keratinocytes grow as monolayers and are
not able to grow and differentiate in stratiﬁed squamous
epithelium as observed in the normal human cervix, but
only reach an incomplete terminal differentiation[6-7].
Animal models established in immunocompromised
mice reconstitute conditions observed in vivo mimick-
ing the physiologic microenvironment of cervical
carcinoma, but these may also show false effects on
tumor progression and molecular mechanisms of the
disease due to the differences between mice and
humans[5]. To overcome the above difﬁculties, in vitro
3-D tumor models with different human cells have been
progressively explored to enable accurate human tissue
reproduction[8]. 3-D in vitro models have an important
role in tumor biology and provide important insights
into cancer research. They enhance our understanding
of tissue organization, cellular differentiation and
provide us a better understanding of tumor behavior.
The 3-D ECM and its receptors can promote normal
epithelial polarity and differentiation[9]. Various techni-
ques have been developed for the construction of 3-D in
vitro tumor models, such as cell-seeding 3-D scaf-
folds[10], hydrogel embedding[11], microﬂuidic chips[12]
or cell patterning[13]. Tissue engineering developments
have further improved the diversity and quality of 3-D
in vitromodels which take them one step closer to the in
vivo situation. However, each of the represented models
has its advantages and limitations. One model is
organotypic epithelial “raft” culture system that allows
proliferation and full differentiation of keratinocyte
monolayers by culturing cells on collagen gels at the air-
liquid interface[14-16]. Normal keratinocytes grown in
this model stratify and fully differentiate in a similar
way to normal squamous epithelium[16]. Another model
that mimics the native state in the skin is the system
where keratinocytes are grown on a de-epidermized or
devitalized dermis, on which cells are able to grow at
the air–liquid interface[17-20]. The latter model is
considered more physiologically relevant as the cell's
growing conditions are similar to the in vivo situation,
and the diffusion of nutrients from the underlying
dermis into the epidermis can be observed[16]. In
addition, the de-epidermised dermal (DED) scaffold
uses a human acellular dermis to construct a new
multilayered epidermis to preserve the basement
membrane which is critical for keratinocytes attachment
in vitro[21].
3-D in vitro systems closely recapitulate the 3-D
organization of cells and ECM as seen in in vivo tissues.
To mimic the human cervix in vitro, i.e., its multilayered
tissue organization and its interactions with ECM, a 3-D
in vitro models of normal and cancer cervix were
developed and the method used in this current research
was adopted and modiﬁed from DED model of human
skin[21-22]. The de-epidermised dermis was used as a
scaffold for both in vitro models. This system is an
inexpensive alternative to other commercially available
3-D in vitro models and a viable alternative to animal
testing. It can be widely used to assess the efﬁcacy of
drugs, to estimate dosage of new therapies and to
develop tumor vaccines. In this study, a list of
biomarkers was used to conﬁrm and validate the
reliability of proposed in vitro systems. Cytokeratin
biomarkers were used to assess the reliability of the 3-D
in vitro model of the cervix. As in cervical cancer
tissues, the pattern of cytokeratins is often disorga-
nized[23], a differentiation biomarker MAX dimerisation
protein 1 (Mad 1) was used to assist in evaluating the 3-
D cervical cancer model.
Materials and methods
The immortalized human keratinocytes cell line
NTERT and the cervical cancer cell line C33A were
purchased from ATCC (ATCC, UK). C33A cell lines
were grown in RPMI (Gibco Invitrogen, UK) media
supplemented with 10% fetal bovine serum (FBS,
BioSera, UK) and 1% penicillin/streptomycin antibiotic
(Sigma, UK). NTERT cells were grown in cytokerati-
nocyte-SFM medium with L-glutamine, without cal-
cium chloride (Gibco Invitrogen, UK) supplemented
with cytokeratinocyte-SFM supplement human recom-
binant epidermal growth factor (2.5 μg/L) and bovine
pituitary extract (BPE) (25 mg/L) (Gibco Invitrogen).
Both cell lines were grown at 37°C in a humidiﬁed
atmosphere of 5% CO2 with the media being changed
every 2-3 days as required. To create the desired
microenvironment for cells to enable them to grow and
differentiate to the required phenotype, estradiol
(Sigma, UK) at physiologic concentration level of 1
μmol/L[24] was added to the 3-D in vitro models of
normal cervix and cervical cancer. Estradiol can
promote differentiation in cervical epithelial cells[25-26]
and can also increase proliferation and inhibit apoptosis
in cervical cancers[27-31].
Human skin (Euro Skin Bank, Netherlands) was ﬁrst
incubated in sterile PBS for 48 hours and then the
epidermis was removed using a scalpel. The remaining
dermis was cut in small 1.5  1.5 cm2 pieces and
washed three times in sterile PBS. Dermal scaffolds
were incubated for 24 hours with different media
according to the cell line used. Human keratinocyte
NTERT cells and cervical cancer C33A cells were
Modeling human cervical cancer in vitro 241
respectively seeded inside a metal ring on the top of
dermal scaffolds, and left for 2 days to attach (Fig. 1A).
Rings were then removed and dermal scaffolds were
raised and placed on metal meshes for another four to
six weeks at the air–liquid interface to allow cell
stratiﬁcation and differentiation (Fig. 1B). At least three
dermal scaffolds were prepared for each cell line used.
After three weeks samples were washed in PBS and
ﬁxed in 4% paraformaldehyde for 48 hours at 4°C. After
ﬁxation, samples were processed, wax embedded and
cut into 6 mm sections for staining.
Slides were stained using standard immunohisto-
chemistry (IHC) methods published elsewhere[32]. In
brief, parafﬁn embedded tissue blocks were cut into
6μm sections, dewaxed and rehydrated through graded
alcohol to water. Sections were then either stained with
hematoxylin and eosin, or incubated with primary
antibodies (Table 1) followed by avidin biotin complex
(ABC) staining methods dehydration, clearing and
mounting in DePeX (BHD, UK). Images were captured
using the Image-Pro Express 6.3 program. Results were
graded by two researchers independently and then
recorded according to the number of positive cells in the
tissues studied. “+” represents 1 to 5 positive cells;
“++” represents 5 to 20 positive cells and “+++”
represents 20 or more positive cells. Sections where
no staining was detected were classiﬁed as negative
(–ve).
Results
NTERT cells were grown in our 3-D in vitro model
and served as a control model of cervical tissue. After 4-
6 weeks of incubation, human keratinocytes managed to
grow on the de-epidermised dermis and formed multi-
layered structures. IHC analysis revealed that the
Fig. 1 The 3-D in vitro model of the cervix. A: Cells were seeded on dermal scaffold. B: The scaffold is placed on metal mesh to enable air-
liquid growing conditions.
Table 1 Antibodies used in immunochemical staining
1° Ab Ig type Concentration Antigen retrieval Serum 2 ° Ab
Anti-cytokeratin [CK5]
(Rabbit monoclonal)
(Abcam)
IgG 1 μg/mL
Citrated buffer x1, heated for
20 minutes
horse
Biotinylated
anti-rabbit IgG
Anti-cytokeratin 10 [CK10]
(Mouse monoclonal)
(Abcam)
IgG1 1 μg/mL
Citrated buffer x1, heated for
20 minutes
horse
Biotinylated
anti-mouse IgG
Anti-cytokeratin 19 [CK19]
(Mouse monoclonal)
(Abcam)
IgG2a 1 μg/mL
Citrated buffer x1, heated for
20 minutes
horse
Biotinylated
anti-mouse IgG
Mad1 (Rabbit polyclonal)
(Santa Cruz Biotechnology)
IgG 2 μg/mL 0.1% Triton-100, 10 minutes horse
Biotinylated
anti-rabbit IgG
Isotypic control
(Goat anti-mouse) (Abcam)
IgG1
5 μg/mL
10 μg/mL
Citrated buffer x1, heated for
20 minutes
0.1% Triton-100, 10 minutes
horse
Biotinylated
anti-goat IgG
Isotypic control
(Goat anti-mouse) (Abcam)
IgG2a
1.1 μg/mL
38 μg/mL
0.1% Triton-100, 20 minutes horse
Biotinylated
anti-goat IgG
Isotypic control
(Goat anti-mouse) (Abcam)
IgG
2 μg/mL
1.53 μg/mL
0.1% Triton-100, 20 minutes horse
Biotinylated
anti-goat IgG
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NTERT model was positively stained with cytokeratin
10 with the staining seen in the upper most stratiﬁed
layer of the epithelium as seen in a normal cervix.
Cytokeratin 5 expression was seen mostly in either the
entire cell layer or in the basal part of tissue depending
on the 3-D in vitro model thickness achieved and this is
consistent with the staining pattern seen in a normal
cervix (Fig. 2).
Cytokeratin 19 is normally seen in the basal cell layer
of the normal cervix. The NTERT 3-D in vitro model
sections were mostly negative for cytokeratin 19, with
only weak staining for single cells found in the basal
layer (Fig. 2). Two negative controls were included, one
of which was an internal negative control where primary
antibody was omitted and the other a negative isotypic
control, where primary antibody was replaced with
normal IgG from the same species using the same
isotype at the same concentration.
C33A cells were then grown in our 3-D in vitromodel
to serve as a model of cervical cancer. Staining results
showed that the cytokeratin distribution pattern
resembled a typical cervix cancerous tissue, where
weak or no staining for cytokeratin 10 and cytokeratin 5
was detected whereas cytokeratin 19 was expressed in
different layers of artiﬁcial tissue model (Fig. 3).
Expression of Mad 1 differentiation marker
MAX dimerization protein 1 (Mad1) is a transcrip-
tional repressor that is produced in differentiating cells
and was used as a differentiation marker to characterize
the cell maturation and differentiation processes
observed when cells were grown at a air-liquid interface
in the 3-D in vitromodel of cervical cancer. In the C33A
3-D in vitro model, cells in the upper, most differ-
entiated layer were stained with Mad1 (Fig. 4).
Discussion
To gain a better insight into mechanisms of human
cancer pathology and to ﬁnd new anticancer therapies,
reliable, physiologically relevant and cost effective in
vitro models are needed. In this study, we have
developed a 3-D in vitro model to allow in vitro
reconstruction of the normal cervix and cervical cancer.
Fig. 2 The 3-D in vitro models of normal cervix (magniﬁcation 400). A: H&E staining; B-D: immunhistochemistry of the cervix model;
B: cytokeratin 5 positively stained cells are found in the basal cell layer. C: Cytokeratin 10 positively stained cells are seen in the upper layer.
D: Cells were negative for cytokeratin 19 with few positively stained cells in the basal layer. Arrows point to positively stained cells.
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Previous studies showed that under conventional
culture conditions where keratinocytes were grown in
plastic petri dishes or ﬂasks as monolayers, they could
only reach an incomplete terminal differentiation and
were not able to form multiple cell layers as observed in
the human cervix[6-7,19]. Terminal differentiation of
NTERT cells was observed in our multilayered 3-D
model of normal cervix. Cultured C33A cancer cells in
the proposed model resulted in signiﬁcant tumor
formation in a 3-D fashion, with some differentiated
cells found in the most superﬁcial layer. One of the
possible reasons for the cells to be able to form tissue
like structures in this in vitro model proposed in our
study is that they are surrounded by a natural
environment of human dermis, where nutrients are
naturally transported from the underlying media and at
the same time most superﬁcial cells are exposed to the
liquid air interface.
To evaluate the accuracy of our models, we compared
the expression of cytokeratins 5, 10 and 19 in the
created 3-D in vitro system of normal cervix with the
expression of the same cytokeratins seen in normal
human cervix in vivo. Cytokeratins (CK), also known as
keratins (K) constitute the largest intermediate ﬁlament
protein subgroup and represent a multigene family with
more than 20 different types of polypeptides. They are
the major structural proteins of epithelial cells and are
Fig. 4 Immunohistochemical staining of Mad 1 from C33A 3-D
in vitro model of cervical cancer. Positive stained cells are detected
in the upper most differentiated layer of the model. Arrows point to
positively stained cells. The image is taken at magniﬁcation of 200.
Fig. 3 The C33A 3-D in vitro model of cervical cancer at magniﬁcation of 200. A: H&E staining; B-D: immunhistochemical staining of
the cervical cancer model; B: cytokeratin 5 negatively stained; C: cytokeratin 10 weakly stained; D: Cytokeratin 19 is detected in different layers
of the 3-D in vitro model. Arrows point to positively stained cells.
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divided into acidic type I (CK9-CK20) and basic type II
(CK1-CK8) cytokeratins[33-34]. The main function of
cytokeratins is to maintain the epithelial cell integrity
and to form the cytoskeleton of epithelial cells[34-35].
Cytokeratins have a speciﬁc distribution pattern in
epithelial tissues[36-37]. Changes in the pattern of
cytokeratin expression during neoplastic transformation
in the cervix have been shown in several studies[38-40].
Table 2 represents different patterns of cytokeratin
expression in non-malignant and cancerous cervical
tissue[23,34,40-47]. Of particular interest are the changes
of cytokeratins 19, 10 and 5.
Cytokeratin 10 is a member of the type I keratin
family and it is a suprabasal differentiation marker in
ectocervical epithelium restricted to skin and cervix[43].
Whenever cytokeratin 10 is expressed in invasive
carcinomas, it is associated with the grade of differ-
entiation and is expressed in well-differentiated areas
and keratin pearls of squamous carcinomas[23,40,42].
Cytokeratin 19 is an intermediate type I keratin, the
smallest known acidic keratin of 40 kDa, that is not
paired with a basic keratin in epithelial cells. This
keratin is speciﬁcally found in the periderm, the
transiently superﬁcial layer that envelops the develop-
ing epidermis[34,44]. Cytokeratin 19 has not been
detected in the epidermis of adult human skin and its
presence is restricted to the outer root sheath of the hair
follicle[45-46]. This cytokeratin is found only in the basal
layer of normal epithelium of the cervix and in the full
thickness of metaplastic cervical epithelium[43]. Cyto-
keratin 5 is a neutral-basic cytokeratin expressed during
differentiation of simple and stratiﬁed epithelial tissues.
Cytokeratin 5 is type II keratin that is expressed mostly
in the basal layer of the epidermis with its family
member acidic keratin 14[47]. In this study, cytokeratin 5
and 10 expression in NTERT 3-D in vitro model
corresponded with staining seen in the normal cervix.
Cytokeratin 19 was weakly expressed and found only in
a few NTERT cells, but the localization of these
positively stained cells corresponded to its in vivo
expression in the normal cervix. Moreover, we found
that C33A cells when grown in our 3-D system showed
cytokeratin distribution characteristic of typical cancer-
ous tissue, where no positivity for cytokeratin 5, and
weak or no positivity for cytokeratin 10 was observed,
whereas cytokeratin 19 was expressed in different
layers. In addition to cytokeratins, another differentia-
tion marker, Mad 1, was used to indicate whether any
differentiation process could be observed in our cervical
cancer model. The Mad1 differentiation marker is a
basic helix–loop–helix–leucine zipper protein that is a
transcriptional repressor produced in differentiating
cells[48-49]. Mad1 is detected in differentiating epithelial
cells of the suprabasal layers of normal epidermis[50]
and its expression extends from the spinous to super-
ﬁcial layer[51]. This transcriptional repressor is
expressed at low levels in proliferating cells and its
expression increases during differentiation of epithelial
cells[50,52]. Mad 1 expression is associated with growth
arrest whereas loss of its expression is related with the
progression to invasive, poorly-differentiated can-
cers[50,52]. With increasing severity of dysplasia, the
expression of Mad 1 is progressively shifted to more
superﬁcial layers and the immunostaining intensity is
reduced[51]. In this study, the expression of Mad1
conﬁrmed that the partial differentiation process
occurred in cancer cells after culturing them in the 3-
D conditions.
Advances of the presented 3-D model have enabled
direct assembly of normal human keratinocytes,
cervical cancer cells and ECM of human de-epider-
mised dermis to form in vitro like cellular models. This
promising technique has offered an inexpensive solu-
tion to culture a variety of cell types under 3-D culture
conditions, also enabled us to manipulate a particular
cell of interest and to study speciﬁc interactions in a
Table 2 Different patterns of cytokeratins expression in non-malignant and malignant cervical tissue, where “ – ” represents
negative staining, “+” representsweak positive, “ – /+”represents negative or weak positive, “++”represents positive and “+++”
representsstrongly positive staining.
Non- malignant tissue Malignant tissue
Neutral-basal or acidic Neutral-basal Acidic Neutral-basal Acidic
Types of Keratin
Cytokeratin
-1
Cytokeratin
-5
Cytokeratin
-10
Cytokeratin
-19
Cytokeratin
-14
Cytokeratin
-1
Cytokeratin
-5
Cytokeratin
-10
Cytokeratin
-19
Cytokeratin
-14
Expression
levels of
different
keratins in
stratiﬁed
squamous
epithelia
of cervix
Non-
keratinizing
intermediate
and
superﬁcial
cells
+ + + – ++ – /+ + – /+ +++ +
Basal cells – +++ – ++ +++ – /+ + – /+ +++ +
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well-deﬁned environment. The functionality of the
proposed model may provide us better insights in
human cervical cancers and create effective therapeutic
designs for patients with cervical carcinoma.
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